{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/angina/goals-outcome-measures/audit-criteria/","result":{"pageContext":{"chapter":{"id":"3c2825f8-cb3b-5b34-9ebb-b3a46c766ad4","slug":"audit-criteria","fullItemName":"Audit criteria","depth":2,"htmlHeader":"<!-- begin field b9f1d4fd-9723-4c40-9d38-de81e9620577 --><h2>Audit criteria</h2><!-- end field b9f1d4fd-9723-4c40-9d38-de81e9620577 -->","summary":null,"htmlStringContent":"<!-- begin item 9a63444f-e0cc-4261-8f92-c02e6273b590 --><!-- begin field 5ad0a7c3-2676-4fb6-a1e2-acf4a1b0ae23 --><p>The National Institute for Health and Care Excellence have developed a clinical audit tool that can be used to measure current practice in the management of stable angina against the recommendations in the NICE guideline.The audit criteria are shown in Table 1. The full audit tool is available from the NICE website (<a href=\"http://www.nice.org.uk/\" data-hyperlink-id=\"35501ec5-a512-41cd-8640-a9920120ffb7\">www.nice.org.uk</a>).</p><p><strong>Table 1.</strong> NICE audit criteria for management of stable angina</p><table><tbody><tr><td colspan=\"2\"><strong>Preventing and treating episodes of angina</strong></td></tr><tr><td colspan=\"1\">Criterion 1</td><td colspan=\"1\">People with a diagnosis of stable angina should be offered a short acting nitrate for preventing and treating episodes of angina</td></tr><tr><td colspan=\"2\">Drugs for secondary prevention of cardiovascular disease</td></tr><tr><td colspan=\"1\">Criterion 2</td><td colspan=\"1\">Healthcare professionals should consider prescribing aspirin 75 mg daily for people with stable angina</td></tr><tr><td colspan=\"1\">Criterion 3</td><td colspan=\"1\">Healthcare professionals should consider prescribing angiotensin-converting enzyme (ACE) inhibitors for people with stable angina and diabetes</td></tr><tr><td colspan=\"1\">Criterion 4</td><td colspan=\"1\">People with a diagnosis of stable angina should be offered statin treatment in line with the NICE clinical guideline Lipid modification</td></tr><tr><td colspan=\"2\"><strong>Drugs for treating stable angina</strong></td></tr><tr><td colspan=\"1\">Criterion 5a</td><td colspan=\"1\">People with a diagnosis of stable angina should be offered either a beta blocker or a calcium-channel blocker as first-line treatment for stable angina</td></tr><tr><td colspan=\"1\">Criterion 5b</td><td colspan=\"1\">People with a diagnosis of stable angina should not be routinely offered anti anginal drugs other than beta-blockers or calcium-channel blockers as first-line treatment for stable angina</td></tr><tr><td colspan=\"1\">Criterion 5c</td><td colspan=\"1\">If the person cannot tolerate beta-blockers and calcium-channel blockers or both are contraindicated, healthcare professionals should consider monotherapy with a long-acting nitrate, ivabradine, nicorandil or ranolazine</td></tr><tr><td colspan=\"1\">Criterion 6</td><td colspan=\"1\">People with a diagnosis of stable angina should have their response to treatment reviewed 2–4 weeks after starting drug treatment</td></tr><tr><td colspan=\"1\">Criterion 7a</td><td colspan=\"1\">When symptoms are not satisfactorily controlled on a beta-blocker or a calcium-channel blocker, healthcare professionals should consider either switching to the other option (calcium-channel blocker or beta-blocker) or using a combination of the two</td></tr><tr><td colspan=\"1\">Criterion 7b</td><td colspan=\"1\">When symptoms are not satisfactorily controlled on a beta-blocker or a calcium-channel blocker, and the other option (calcium-channel blocker or beta-blocker) is contraindicated or not tolerated, healthcare professionals should consider a long-acting nitrate, ivabradine, nicorandil or ranolazine as an additional drug</td></tr><tr><td colspan=\"1\">Criterion 8</td><td colspan=\"1\"><p>Healthcare professionals should consider offering a third anti-anginal drug only when: </p><ul><li>The person’s symptoms are not satisfactorily controlled with two anti-anginal drugs and </li><li>They are waiting for revascularisation or revascularisation is not considered appropriate or acceptable</li></ul></td></tr><tr><td colspan=\"2\">[<a class=\"bibliography-reference internal-reference\" href=\"/topics/angina/references/\">NICE, 2011</a>]</td></tr></tbody></table><!-- end field 5ad0a7c3-2676-4fb6-a1e2-acf4a1b0ae23 --><!-- end item 9a63444f-e0cc-4261-8f92-c02e6273b590 -->","topic":{"id":"24c3b3ba-4467-513f-abfe-8ce9696ebacf","topicId":"b8a92113-15ce-47f8-b5f2-29135fbaeb9a","topicName":"Angina","slug":"angina","lastRevised":"Last revised in November 2020","chapters":[{"id":"d037d955-219a-51cb-9b7b-d80e4698480c","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"5b576d3c-d1ef-5582-9049-3daf9166c674","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"6cf8d028-1d6d-5b17-9009-24daa603c2ad","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"a6e68c4e-737d-529e-9f2e-1d371564e243","slug":"changes","fullItemName":"Changes"},{"id":"8b294548-958c-5d4a-994a-d658b034e0ed","slug":"update","fullItemName":"Update"}]},{"id":"c182c0dc-2d1c-56e3-9ddf-42e6c9141f36","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"1551834c-ae66-5b2c-84f5-a2d776dc7567","slug":"goals","fullItemName":"Goals"},{"id":"b81e978d-4230-5023-bc0d-fb2d054d74aa","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"3c2825f8-cb3b-5b34-9ebb-b3a46c766ad4","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"6995e8ae-daff-5a5e-a996-7bdceeea4732","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"ce74d231-e2d6-56f8-ac25-96c7241244cc","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"472866af-8514-57e4-b1d5-e76616c0e906","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"891abedd-d2c4-5a34-8cb6-b56547b6ba9b","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"122479e4-f056-5d94-8c91-9b335aabc39c","slug":"definition","fullItemName":"Definition"},{"id":"7602d977-de51-5c3e-ba00-039a782195fe","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"c395652b-1917-588c-844c-c3d57cfce9ec","slug":"complications","fullItemName":"Complications"},{"id":"6afa1096-05eb-5cd0-9f06-d62a61ee26eb","slug":"prognosis","fullItemName":"Prognosis"},{"id":"0b84b71b-1d99-58d0-a7ba-5bdb9b3f6bd2","slug":"prevalence","fullItemName":"Prevalence"}]},{"id":"77a23b35-11f3-574c-b4c0-818798961d36","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"1c414f08-80ea-5957-8637-b7691da3f4ba","slug":"assessment-of-stable-chest-pain","fullItemName":"Assessment of stable chest pain"},{"id":"aa7c3bff-512c-5ada-919e-f74c0d819710","slug":"confirming-the-diagnosis","fullItemName":"Confirming the diagnosis"},{"id":"7a2866dc-7796-52e4-859a-a7d02908df33","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"},{"id":"9f5fa5d2-ae88-5bdd-892e-f0bc8348f1a8","slug":"awaiting-diagnostic-testing","fullItemName":"Awaiting diagnostic testing"}]},{"id":"bc614509-86f3-56fe-baa9-015bad71459b","fullItemName":"Management","slug":"management","subChapters":[{"id":"97e1a557-e962-51f0-9fd2-26ed6d619574","slug":"new-diagnosis","fullItemName":"Scenario: New diagnosis"},{"id":"244b2360-1f5d-5f3e-8685-b041b97398d3","slug":"routine-review","fullItemName":"Scenario: Routine review"},{"id":"ef455505-25b3-57d4-851c-8db39de1ca9f","slug":"poor-control-on-treatment","fullItemName":"Scenario: Poor control on treatment"}]},{"id":"d18ef561-191a-5df7-a1f7-ef2d79106a0d","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"813aebe7-14a8-557c-bac0-87a6cfe91c34","slug":"nitrates","fullItemName":"Nitrates"},{"id":"a1a4269f-60e8-5f82-938f-f4224de056ff","slug":"ivabradine","fullItemName":"Ivabradine"},{"id":"b276b003-d2f8-5a9d-ab8e-71924285102d","slug":"calcium-channel-blockers","fullItemName":"Calcium-channel blockers"},{"id":"e5a32575-7219-5c2f-b008-229c08a61dd5","slug":"ranolazine","fullItemName":"Ranolazine"},{"id":"ec1ac1aa-2520-5cda-877d-07f3ed8d3453","slug":"beta-blockers","fullItemName":"Beta-blockers"},{"id":"7261389f-2f16-563e-96b2-2543a8a4ee17","slug":"nicorandil","fullItemName":"Nicorandil"}]},{"id":"11c1f888-ca90-5be7-a7a1-2c8d7b44961c","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"3669e04b-2ce6-595d-b4cb-e5abcb213a1e","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"283f72a3-a414-5e7f-9f58-d86340ba7348","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"58238f70-829d-5fd5-bea6-4b71b01a6633","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"985e0900-f162-5892-a6ae-ee6a677babb1","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"d892adf9-3736-5e8b-a845-d4cb6ce084b7","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"c0c74471-a5d7-52eb-bf37-6b038917dce3","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"157e1fd8-63b8-5cc6-a4ad-44ae83612fe9","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"c182c0dc-2d1c-56e3-9ddf-42e6c9141f36","slug":"goals-outcome-measures","fullItemName":"Goals and outcome measures"},"subChapters":[]}}},"staticQueryHashes":["3666801979"]}